GSK plc (ADR)
General ticker "GSK" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $77.9B (TTM average)
GSK plc (ADR) follows the US Stock Market performance with the rate: 41.2%.
Estimated limits based on current volatility of 0.9%: low 48.37$, high 49.17$
Factors to consider:
- Company pays dividends (quarterly): last record date 2025-11-14, amount 0.42$ (Y3.46%)
- Total employees count: 99451 as of 2013
- Price in estimated range
- Earnings for 18 months up through Q2 (+1 year) are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [33.88$, 44.21$]
- 2024-12-30 to 2025-12-30 estimated range: [37.46$, 48.60$]
Financial Metrics affecting the GSK estimates:
- Positive: with PPE of 9.6 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 22.24 > 18.64
- Positive: Operating cash flow per share per price, % of 13.45 > 13.24
- Positive: Return on assets ratio (scaled to [-100,100]) of 6.15 > 6.04
- Negative: Investing cash flow per share per price, % of -4.10 <= -0.66
- Positive: Industry earnings per price (median), % of 5.15 > 4.43
- Negative: 0.79 < Interest expense per share per price, % of 1.32
- Positive: 0 < Industry operating cash flow per share per price (median), % of 5.20
Short-term GSK quotes
Long-term GSK plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | £29,324.00MM | £30,328.00MM | £31,376.00MM |
| Operating Expenses | £22,891.00MM | £23,583.00MM | £27,355.00MM |
| Operating Income | £6,433.00MM | £6,745.00MM | £4,021.00MM |
| Non-Operating Income | £-805.00MM | £-681.00MM | £-544.00MM |
| Interest Expense | £855.53MM | £775.00MM | £657.58MM |
| R&D Expense | £5,488.00MM | £6,223.00MM | £6,401.00MM |
| Income(Loss) | £5,628.00MM | £6,064.00MM | £3,477.00MM |
| Taxes | £707.00MM | £756.00MM | £526.00MM |
| Profit(Loss)* | £4,921.00MM | £4,928.00MM | £2,575.00MM |
| Stockholders Equity | £10,598.00MM | £17,014.76MM | £13,671.00MM |
| Inventory | £5,146.00MM | £7,008.85MM | £5,669.00MM |
| Assets | £60,146.00MM | £75,219.57MM | £59,463.00MM |
| Operating Cash Flow | £8,160.54MM | £7,890.89MM | £6,554.00MM |
| Capital expenditure | £1,407.92MM | £1,633.37MM | £2,982.00MM |
| Investing Cash Flow | £-10,881.55MM | £-2,404.06MM | £-1,229.00MM |
| Financing Cash Flow | £2,048.45MM | £-6,068.58MM | £-4,726.00MM |
| Earnings Per Share** | £2.44 | £2.43 | £1.26 |
| Ordinary share to ADR | 0.50x | 0.50x | 0.50x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.